Recent Options for Phase 1 Formulation Development and Clinical Trial Material Supply - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Recent Options for Phase 1 Formulation Development and Clinical Trial Material Supply
To meet the demands of early-stage development, contract research organizations can evaluate various dosage-form options. The author examines various methods of capsule filling, including binary blends.


Pharmaceutical Technology


Conclusion

The methods of active pharmaceutical ingredient in a capsule, drug in a bottle, liquid in a capsule, or multiple binary blends provide options for getting drug product into the clinic in a short period of time. Although not all the options are capable of reaching commercial scale, they are all capable of supporting early clinical studies and may be used as a path to an eventual commercial dosage form.

Acknowledgment

The author is thankful to Paul Skultety, director of pharmaceutical development services at Xcelience for final review.

Balaji V. Kadri is a manager of the preformulation and formulation-development department at Xcelience, 5415 West Laurel St., Tampa, FL 33647, tel. 813.286.0404, fax 813.286.1105,

References

1. C.H. Dubin, "Formulation Strategies for Poorly Soluble Drugs," Drug Del. Technol. 6 (6), 34–38 (2006).

2. "Xcelodose S Precision Powder Mircodosing System," available at http://www.capsugel.com/pdf/xceloSBorchure.pdf, accessed July 17, 2008.

3. O.J. Murray, W. Dang, and D. Bergstrom, "Using an Electronic Tongue to Optimize Taste-Masking," Pharm. Technol., Outsourcing Resources suppl. 42–52 (Aug. 2004).

4. I. Alashkar, "It Tastes like Medicine," Pharma Quality 30–37 (Dec.–Jan., 2006).

5. M.E. Martelli, "Sublingual and Buccal Medication Administration," in Encyclopedia of Nursing and Allied Health (Thomson Gale, Farmington Hills, MI, 2008), pp. 1–9.

6. J.A. Nicollazzo and B.C. Finnin, "In Vivo and In Vitro Models for Assessing Drug Absorption Across the Buccal Mucosa," in Biotechnology: Pharmaceutical Aspects, vol. VII (Springer US, New York, 2007), pp. 89–111.

7. T.E. Cole, "Liquid Filled and Sealed Hard Gelatin Capsules," Capsugel Library (2000).

8. "Liquid Encapsulation Microspray Sealing (LEMS)," available at http://www.capsugel.com/equipment/cfs1200.php, accessed July 17, 2008.

9. Gattefossé. "Solubility and Bioavailability Enhancers," available at http://www.gattefosse.com/internet/gatt-wk3.nsf/TECHDOCPARCLEF/00000309?OpenDocument&Menu=1/, accessed June 19, 2008.

10. M. Richardson and S. Stegemann, "Filling Two-Piece Hard Gelatin Capsules with Liquids," Tablets & Capsules 3 (1), 97–110 (2006).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here